LIfT BioSciences to present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer
LIfT BioSciences announces grant of €12 million from Ireland’sDisruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy
Comments